Skip to main content
Amit Jain, MD, Oncology, University of Tennessee Health Science Center

AmitJainMD

Oncology

Hematology Oncology Fellow

Dr. Jain is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Jain's full profile

Already have an account?

Summary

  • Dr. Amit Jain is a Heme Onc Doc in Tupelo, MS.

Education & Training

  • University of Tennessee
    University of TennesseeFellowship, Hematology and Medical Oncology, 2020 - 2023
  • University of Tennessee
    University of TennesseeResidency, Internal Medicine, 2017 - 2020
  • Other
    OtherClass of 2015

Certifications & Licensure

  • MS State Medical License
    MS State Medical License 2022 - 2024
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Journal Articles

  • Predictors of Mortality in Metastatic Papillary Renal Cell Cancer  
    • Sidana A, Jain AL (Presenter), Kadakia M, Krane S, Friend J, Muthigi A, Ninos M, Shih J, Srinivasan R., Journal Of Clinical Oncology
  • Outcomes with CDK4/6 inhibitors based on endocrine sensitivity in hormone receptor-positive metastatic breast cancer (HR+ MBC)  
    • Jain AL, Mullins JN, Poorman KA, Chaudhry A, Ranganath HA, Miller EM, Valasareddy P, Smith JR, Ryder J, Winerip M, Schwartzberg LS, Vidal GA, Journal of Clinical Oncology, 2019

Abstracts/Posters

  • Comparison of End-Fire VS. Side-Fire Ultrasound Probes for MRI/TRUS Fusion-Guided Prostate Biopsy.
    Jain AL, Sidana A, Stanik Z, Maruf M, Calio B, Sugano D, Gommella P, Hammerich K, Yan P, Turkbey B, Choyke P, Wood B, Pinto P., Society of Urologic Oncology, San Antonio, 11/2017
  • Urologist's Practice Patterns And Preferences Regarding Focal Therapy For Prostate Cancer.
    • Jain A, Sidana A, Sugano D, Calio B, Maruf M, Choyke P, Turkbey B, Wood BJ, Pinto P, AUA, Boston, 5/2017

Lectures

  • Outcomes with CDK4/6 inhibitors based on endocrine sensitivity in hormone receptor-positive metastatic breast cancer (HR+ MBC). 
    ASCO Annual Meeting 2019 - Chicago, IL - 5/31/2019

Research History

  • Research ScholarNational Cancer Institute, Bethesda, MD2016 - 2017

Professional Memberships

Other Languages

  • Hindi, Tamil

Hospital Affiliations